IL-17D reprograms CD93(+) antigen-presenting cells in the glioblastoma microenvironment.

Restoring IL-17D in glioblastoma reprograms CD93(+) antigen-presenting cells, extending survival by activating immune responses in mouse models.

• Why it matters: Glioblastoma's immunosuppressive microenvironment hampers immunotherapy effectiveness, and understanding how to reverse this suppression could improve treatment outcomes.
• What they did: The study used orthotopic GBM models to show that IL-17D expression is downregulated during tumor development and that restoring it reprograms myeloid cells via CD93, SCARB1, and downstream signaling pathways.
• The result: Restoring IL-17D reshapes the immune landscape of GBM, suggesting its potential as a therapeutic target to enhance immunotherapy efficacy.